Dr Pamela McCall
- Manager of Glasgow Tissue Research Facility (GTRF) (Therapeutic Science Research)
Publications
2020
McAllister, M. J., McCall, P., Dickson, A., Underwood, M. A., Andersen, D., Holmes, E., Market, E., Leung, H. Y. and Edwards, J. (2020) Androgen receptor phosphorylation at serine 81 and serine 213 in castrate-resistant prostate cancer. Prostate Cancer and Prostatic Diseases, 23(4), pp. 596-606. (doi: 10.1038/s41391-020-0235-1) (PMID:32358577)
2017
Roseweir, A. K. , McCall, P., Scott, A., Liew, B., Lim, Z., Mallon, E. A. and Edwards, J. (2017) Phosphorylation of androgen receptors at serine 515 is a potential prognostic marker for triple negative breast cancer. Oncotarget, 8(23), pp. 37172-37185. (doi: 10.18632/oncotarget.16420) (PMID:28415597) (PMCID:PMC5514900)
Bennett, L., Quinn, J. , McCall, P., Mallon, E. A., Horgan, P. G. , McMillan, D. C. , Paul, A. and Edwards, J. (2017) High IKKα expression is associated with reduced time to recurrence and cancer specific survival in oestrogen receptor (ER)-positive breast cancer. International Journal of Cancer, 140(7), pp. 1633-1644. (doi: 10.1002/ijc.30578) (PMID:28006839)
2016
Hatziieremia, S., Mohammed, Z., McCall, P., Willder, J. M., Roseweir, A. K. , Underwood, M. A. and Edwards, J. (2016) Loss of signal transducer and activator of transcription 1 is associated with prostate cancer recurrence. Molecular Carcinogenesis, 55(11), pp. 1667-1677. (doi: 10.1002/mc.22417) (PMID:26495772)
2013
McCall, P., Adams, C.E., Willder, J., Bennett, L., Qayyum, T., Orange, C., Underwood, M. and Edwards, J. (2013) Androgen receptor phosphorylation at serine 308 and serine 791 predicts enhanced survival in castrate resistant prostate cancer patients. International Journal of Molecular Sciences, 14(8), pp. 16656-16671. (doi: 10.3390/ijms140816656) (PMID:23945560) (PMCID:PMC3759930)
Denley, S.M., Jamieson, N.B. , McCall, P., Oien, K.C.S. , Morton, J.P. , Carter, C.R., Edwards, J. and McKay, C.J. (2013) Activation of the IL-6R/Jak/Stat pathway is associated with a poor outcome in resected pancreatic ductal adenocarcinoma. Journal of Gastrointestinal Surgery, 17(5), pp. 887-898. (doi: 10.1007/s11605-013-2168-7)
Willder, J.M. et al. (2013) Androgen receptor phosphorylation at serine 515 by Cdk1 predicts biochemical relapse in prostate cancer patients. British Journal of Cancer, 108(1), pp. 139-148. (doi: 10.1038/bjc.2012.480)
2012
MacKenzie, L. et al. (2012) Nuclear factor κB predicts poor outcome in patients with hormone-naive prostate cancer with high nuclear androgen receptor. Human Pathology, 43(9), pp. 1491-1500. (doi: 10.1016/j.humpath.2011.11.009)
McCall, P. et al. (2012) NFκB signalling is upregulated in a subset of castrate-resistant prostate cancer patients and correlates with disease progression. British Journal of Cancer, 107(9), pp. 1554-1563. (doi: 10.1038/bjc.2012.372)
2011
Marsella-Hatziieremia, S., McCall, P. and Edwards, J. (2011) Signalling pathways and gene expression profiles in prostate cancer. In: Spiess, P. (ed.) Prostate Cancer: From Bench to Bedside. InTech, pp. 93-114. ISBN 9789533073316 (doi: 10.5772/26971)
McCall, P.,, Catlow, J., McArdle, P.A., McMillan, D.C. and Edwards, J. (2011) Tumoral C-reactive protein and nuclear factor kappa-B expression are associated with clinical outcome in patients with prostate cancer. Cancer Biomarkers, 10(2), pp. 91-99. (doi: 10.3233/CBM-2012-0236)
Mukherjee, R., Mcguinness, D.H. , McCall, P., Underwood, M. A., Seywright, M., Orange, C. and Edwards, J. (2011) Upregulation of MAPK pathway is associated with survival in castrate-resistant prostate cancer. British Journal of Cancer, 104(12), pp. 1920-1928. (doi: 10.1038/bjc.2011.163) (PMID:21559022) (PMCID:PMC3111196)
2010
Teo, K., McVitty, C., Mitchell, T., McCall, P. and Edwards, J. (2010) Cyclin D1 expression influences overall survival in androgen independent prostate cancer. British Journal of Cancer, 97(S6), p. 26. (doi: 10.1002/bjs.7351)
2009
McCall, P., McKenzie, L., Lim, Y.R., Sewright, M., Orange, C. and Edwards, J. (2009) The role of Androgen receptor phosphorylation at three different serine phosphorylation sites in the development of hormone refractory prostate cancer. European Urology Supplements, 8(4), p. 247. (doi: 10.1016/S1569-9056(09)60502-9)
2008
McCall, P., Gemmell, L.K., Mukherjee, R., Bartlett, J.M.S. and Edwards, J. (2008) Phosphorylation of the androgen receptor is associated with reduced survival in hormonerefractory prostate cancer patients. British Journal of Cancer, 98(6), pp. 1094-1101. (doi: 10.1038/sj.bjc.6604152)
McCall, P., Witton, C.J., Grimsley, S., Nielsen, K.V. and Edwards, J. (2008) Is PTEN loss associated with clinical outcome measures in human prostate cancer? British Journal of Cancer, 99(8), pp. 1296-1301. (doi: 10.1038/sj.bjc.6604680)
Traynor, P., McGlynn, L.M., Mukherjee, R., Grimsley, S.L.S., Bartlett, J.M.S. and Edwards, J. (2008) An increase in N-Ras expression is associated with development of hormone refractory prostate cancer in a subset of patients. Disease Markers, 24(3), pp. 157-165.
2007
Tam, L., McGlynn, L.M., Traynor, P., Mukherjee, R., Bartlett, J.M.S. and Edwards, J. (2007) Expression levels of the JAK/STAT pathway in the transition from hormone-sensitive to hormone-refractory prostate cancer. British Journal of Cancer, 97(3), pp. 378-383. (doi: 10.1038/sj.bjc.6603871)
Teo, K., Gemmell, L., Mukherjee, R., Traynor, P. and Edwards, J. (2007) Bad expression influences time to androgen escape in prostate cancer. BJU International, 100(3), pp. 691-696. (doi: 10.1111/j.1464-410X.2007.07001.x)
2006
Edwards, J., Traynor, P., Munro, A., Pirrett, C.F., Dunne, B. and Bartlett, J.M.S. (2006) The role of HER1-HER4 and EGFRvIII in hormone-refractory prostate cancer. Clinical Cancer Research, 12(1), pp. 123-130. (doi: 10.1158/1078-0432.CCR-05-1445)
Articles
McAllister, M. J., McCall, P., Dickson, A., Underwood, M. A., Andersen, D., Holmes, E., Market, E., Leung, H. Y. and Edwards, J. (2020) Androgen receptor phosphorylation at serine 81 and serine 213 in castrate-resistant prostate cancer. Prostate Cancer and Prostatic Diseases, 23(4), pp. 596-606. (doi: 10.1038/s41391-020-0235-1) (PMID:32358577)
Roseweir, A. K. , McCall, P., Scott, A., Liew, B., Lim, Z., Mallon, E. A. and Edwards, J. (2017) Phosphorylation of androgen receptors at serine 515 is a potential prognostic marker for triple negative breast cancer. Oncotarget, 8(23), pp. 37172-37185. (doi: 10.18632/oncotarget.16420) (PMID:28415597) (PMCID:PMC5514900)
Bennett, L., Quinn, J. , McCall, P., Mallon, E. A., Horgan, P. G. , McMillan, D. C. , Paul, A. and Edwards, J. (2017) High IKKα expression is associated with reduced time to recurrence and cancer specific survival in oestrogen receptor (ER)-positive breast cancer. International Journal of Cancer, 140(7), pp. 1633-1644. (doi: 10.1002/ijc.30578) (PMID:28006839)
Hatziieremia, S., Mohammed, Z., McCall, P., Willder, J. M., Roseweir, A. K. , Underwood, M. A. and Edwards, J. (2016) Loss of signal transducer and activator of transcription 1 is associated with prostate cancer recurrence. Molecular Carcinogenesis, 55(11), pp. 1667-1677. (doi: 10.1002/mc.22417) (PMID:26495772)
McCall, P., Adams, C.E., Willder, J., Bennett, L., Qayyum, T., Orange, C., Underwood, M. and Edwards, J. (2013) Androgen receptor phosphorylation at serine 308 and serine 791 predicts enhanced survival in castrate resistant prostate cancer patients. International Journal of Molecular Sciences, 14(8), pp. 16656-16671. (doi: 10.3390/ijms140816656) (PMID:23945560) (PMCID:PMC3759930)
Denley, S.M., Jamieson, N.B. , McCall, P., Oien, K.C.S. , Morton, J.P. , Carter, C.R., Edwards, J. and McKay, C.J. (2013) Activation of the IL-6R/Jak/Stat pathway is associated with a poor outcome in resected pancreatic ductal adenocarcinoma. Journal of Gastrointestinal Surgery, 17(5), pp. 887-898. (doi: 10.1007/s11605-013-2168-7)
Willder, J.M. et al. (2013) Androgen receptor phosphorylation at serine 515 by Cdk1 predicts biochemical relapse in prostate cancer patients. British Journal of Cancer, 108(1), pp. 139-148. (doi: 10.1038/bjc.2012.480)
MacKenzie, L. et al. (2012) Nuclear factor κB predicts poor outcome in patients with hormone-naive prostate cancer with high nuclear androgen receptor. Human Pathology, 43(9), pp. 1491-1500. (doi: 10.1016/j.humpath.2011.11.009)
McCall, P. et al. (2012) NFκB signalling is upregulated in a subset of castrate-resistant prostate cancer patients and correlates with disease progression. British Journal of Cancer, 107(9), pp. 1554-1563. (doi: 10.1038/bjc.2012.372)
McCall, P.,, Catlow, J., McArdle, P.A., McMillan, D.C. and Edwards, J. (2011) Tumoral C-reactive protein and nuclear factor kappa-B expression are associated with clinical outcome in patients with prostate cancer. Cancer Biomarkers, 10(2), pp. 91-99. (doi: 10.3233/CBM-2012-0236)
Mukherjee, R., Mcguinness, D.H. , McCall, P., Underwood, M. A., Seywright, M., Orange, C. and Edwards, J. (2011) Upregulation of MAPK pathway is associated with survival in castrate-resistant prostate cancer. British Journal of Cancer, 104(12), pp. 1920-1928. (doi: 10.1038/bjc.2011.163) (PMID:21559022) (PMCID:PMC3111196)
Teo, K., McVitty, C., Mitchell, T., McCall, P. and Edwards, J. (2010) Cyclin D1 expression influences overall survival in androgen independent prostate cancer. British Journal of Cancer, 97(S6), p. 26. (doi: 10.1002/bjs.7351)
McCall, P., McKenzie, L., Lim, Y.R., Sewright, M., Orange, C. and Edwards, J. (2009) The role of Androgen receptor phosphorylation at three different serine phosphorylation sites in the development of hormone refractory prostate cancer. European Urology Supplements, 8(4), p. 247. (doi: 10.1016/S1569-9056(09)60502-9)
McCall, P., Gemmell, L.K., Mukherjee, R., Bartlett, J.M.S. and Edwards, J. (2008) Phosphorylation of the androgen receptor is associated with reduced survival in hormonerefractory prostate cancer patients. British Journal of Cancer, 98(6), pp. 1094-1101. (doi: 10.1038/sj.bjc.6604152)
McCall, P., Witton, C.J., Grimsley, S., Nielsen, K.V. and Edwards, J. (2008) Is PTEN loss associated with clinical outcome measures in human prostate cancer? British Journal of Cancer, 99(8), pp. 1296-1301. (doi: 10.1038/sj.bjc.6604680)
Traynor, P., McGlynn, L.M., Mukherjee, R., Grimsley, S.L.S., Bartlett, J.M.S. and Edwards, J. (2008) An increase in N-Ras expression is associated with development of hormone refractory prostate cancer in a subset of patients. Disease Markers, 24(3), pp. 157-165.
Tam, L., McGlynn, L.M., Traynor, P., Mukherjee, R., Bartlett, J.M.S. and Edwards, J. (2007) Expression levels of the JAK/STAT pathway in the transition from hormone-sensitive to hormone-refractory prostate cancer. British Journal of Cancer, 97(3), pp. 378-383. (doi: 10.1038/sj.bjc.6603871)
Teo, K., Gemmell, L., Mukherjee, R., Traynor, P. and Edwards, J. (2007) Bad expression influences time to androgen escape in prostate cancer. BJU International, 100(3), pp. 691-696. (doi: 10.1111/j.1464-410X.2007.07001.x)
Edwards, J., Traynor, P., Munro, A., Pirrett, C.F., Dunne, B. and Bartlett, J.M.S. (2006) The role of HER1-HER4 and EGFRvIII in hormone-refractory prostate cancer. Clinical Cancer Research, 12(1), pp. 123-130. (doi: 10.1158/1078-0432.CCR-05-1445)
Book Sections
Marsella-Hatziieremia, S., McCall, P. and Edwards, J. (2011) Signalling pathways and gene expression profiles in prostate cancer. In: Spiess, P. (ed.) Prostate Cancer: From Bench to Bedside. InTech, pp. 93-114. ISBN 9789533073316 (doi: 10.5772/26971)